Josep Domingo-Domenech, Director of Urology Translational Research Mayo Clinic, shared a post on LinkedIn:
“Thrilled to share our new Review in Nature Reviews Urology celebrating the 20th year therapeutic milestone of taxanes becoming a mainstay treatment for prostate cancer patients.
We perform an up-to-date analysis of the pivotal role of taxanes in the treatment of prostate cancer, discuss reasons why taxanes remain effective and how the mechanisms that confer resistance to taxanes in prostate cancer might be exploited to develop more effective therapeutic strategies.
Great collaboration with Drs. Daniel Petrylak and Veronica Rodriguez-Bravo!”
Title: 20 years of taxane therapy in prostate cancer — the past, present and future
Authors: Marc Carceles-Cordon, Veronica Rodriguez-Bravo, Daniel P. Petrylak, Josep Domingo-Domenech
You can read the full article in Nature Reviews Urology.
